Thelansis

Primary Progressive Aphasia (PPA) Market Outlook Thelansis’s “Primary Progressive Aphasia (PPA) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Primary Progressive Aphasia (PPA) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest ...

Primary Progressive Aphasia (PPA) Market Outlook Thelansis’s “Primary Progressive Aphasia (PPA) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Primary Progressive Aphasia (PPA) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Primary Progressive Aphasia (PPA) Overview Primary Progressive Aphasia (PPA) is a neurodegenerative disorder primarily affecting language abilities. It is classified into three variants based on clinical characteristics, including logopenic variant PPA (lvPPA), nonfluent agrammatic PPA (nfaPPA), and semantic variant PPA (svPPA). The symptoms of PPA can vary and may include difficulty with speech, word find...

  Primary progressive aphasia (PPA) is a progressive loss of specific language functions with relative sparing of other cognitive domains, at least for the first few years of the illness. Based on the constellation of symptoms, PPA has been recently classified into a nonfluent, semantic, or logopenic variant. Nonfluent variant PPA is characterized by dysfluent and effortful speech, often combined with agrammatism. Also, some patients have initially predominant apraxia of speech. The neuroimaging findings in nfvPPA are in most cases progressive atrophy within the left inferior, opercular, and insular regions. Pathology is a tauopathy (FTLD-T), most often Pick's disease or CBD. Semantic variant PPA, on the other hand is characterized by fluent, but circumlocutory speech, then severe anomia and word-finding difficulties, all being associated with a progressive loss of lexical-semantic knowledge. As the disease progresses, the semantic impairment typically becomes multimodal. The cli...

 Primary Progressive Aphasia (PPA) is a neurodegenerative disorder primarily affecting language abilities. It is classified into three variants based on clinical characteristics, including logopenic variant PPA (lvPPA), nonfluent agrammatic PPA (nfaPPA), and semantic variant PPA (svPPA). The symptoms of PPA can vary and may include difficulty with speech, word finding, comprehension of language, and naming objects and people. PPA is a result of neurodegeneration, which refers to the progressive death of brain cells that cannot be attributed to other causes, such as head trauma, stroke, infection, or cancer. The three most commonly encountered underlying diseases causing PPA are frontotemporal lobar degeneration with abnormal TDP-43 accumulation (FTLD-TDP-43), frontotemporal lobar degeneration with abnormal tau protein accumulation (FTLD-tau), and Alzheimer's disease (AD). When abnormal proteins associated with Alzheimer's disease or one of the forms of frontotemporal lobar dege...